Cell line · CVCL_1670
Papers54
1 to 20 of 54
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| An MMP-14/STAT3 feedback loop upregulates PD-L1 to drive immunosuppression and tumorigenesis in bladder cancer. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Rapid normal fibroblast-tumor crosstalk promotes cancer-associated fibroblast-like activation and attenuates mitomycin C cytotoxicity in bladder cancer. | J Cell Commun Signal | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A Spatial Atlas of Muscle-Invasive Bladder Cancer Reveals Lineage-Specific Vulnerabilities and Immune Architecture. | Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells. | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Oncolytic virotherapy provides a potent therapy option for squamous bladder cancer. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| A Genome-Wide Synthetic Lethal Screen Identifies Spermidine Synthase as a Target to Enhance Erdafitinib Efficacy in FGFR-Mutant Bladder Cancer. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| DGKα Enhances Tumorigenic Activity in Bladder Cancer Patients With Chronic Kidney Disease. | Cancer Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| HLA-E and NKG2A Mediate Resistance to BCG Immunotherapy in Non-Muscle-Invasive Bladder Cancer. | bioRxiv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Proteomic analysis of the urothelial cancer landscape. | Nat Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis. | Cell Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma. | Oncoimmunology | 2023 | Its Methods give the RRID and name the line | PubMed | |
| RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations. | Cancer Discov | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PABPN1 regulates mRNA alternative polyadenylation to inhibit bladder cancer progression. | Cell Biosci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer. | Cancer Cell | 2022 | Its Methods give the RRID and name the line | PubMed | |
| ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. | JCI Insight | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Aberrant Nuclear Export of circNCOR1 Underlies SMAD7-Mediated Lymph Node Metastasis of Bladder Cancer. | Cancer Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells. | Oncotarget | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1670/papers